Longeveron News

Longeveron Believes Cash and Cash Equivalents Will Fund Oper Expenses and Cap Expenditure Requirements Into 4Q

Longeveron Believes Cash and Cash Equivalents Will Fund Oper Expenses and Cap Expenditure Requirements Into 4Q

Dow JonesMay 15 04:35

Longeveron: Phase 2b Clinical Trial Evaluating Lomecel-BTM in Rare Pediatric Disease HLHS on Track for Completing Enrollment by End of 2024 >LGVN

Longeveron: Phase 2b Clinical Trial Evaluating Lomecel-BTM in Rare Pediatric Disease HLHS on Track for Completing Enrollment by End of 2024 >LGVN

Dow JonesMay 15 04:34

Longeveron 1Q Rev $548,000 >LGVN

Longeveron 1Q Rev $548,000 >LGVN

Dow JonesMay 15 04:18

Longeveron Q1 EPS $(1.61) Beats $(2.00) Estimate, Sales $548.00K Beat $100.00K Estimate

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.00) by 19.5 percent. This is a 27.15 percent increase over losses of $(2.21) pe

BenzingaMay 15 04:11

Earnings Flash (LGVN) LONGEVERON Posts Q1 Revenue $548,000

04:10 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (LGVN) LONGEVERON Posts Q1 Revenue $548,000

MT NewswiresMay 15 04:10

Longeveron | 10-Q: Quarterly report

SEC announcementMay 15 04:09 · Announcements

Longeveron Board Reshuffle and Nasdaq Compliance Efforts

TipRanksMay 11 04:43

Longeveron Announces Board Transitions

Seeking AlphaMay 11 04:15

Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN

Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN

Dow JonesMay 11 04:06

Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN

Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN

Dow JonesMay 11 04:06

Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same

Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same

BenzingaMay 8 02:55

Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'

Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'

BenzingaMay 3 02:26

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results

GlobeNewswireMay 2 20:03

Longeveron Files Prospectus for Secondary Offering

Longeveron (LGVN) on Tuesday filed a preliminary prospectus for resale of about five million class A common shares by selling stockholders. The company said it will not get any of the proceeds from th

MT NewswiresMay 1 01:22

Longeveron Is Maintained at Buy by HC Wainwright & Co.

Longeveron Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 30 00:48

HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.

HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.

Zhitong FinanceApr 30 00:40

HC Wainwright & Co. Maintains Buy on Longeveron, Adjusts Price Target To $12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy, adjusts target to $12 from $6.

BenzingaApr 30 00:39

Longeveron Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 574.16% HC Wainwright & Co. $6 → $12 Maintains Buy 12/04/2023 237.08% HC Wainwright & Co. → $6

BenzingaApr 30 00:36

Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)

TipRanksApr 29 18:20

Longeveron to Present at the Planet MicroCap Showcase

Globe NewswireApr 26 04:05